Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Kiran C. Patki"'
Autor:
Arshad M. Khanani, MD, MA, Raj K. Maturi, MD, Nika Bagheri, MD, Benjamin Bakall, MD, PhD, David S. Boyer, MD, Stephen S. Couvillion, MD, Dilsher S. Dhoot, MD, Nancy M. Holekamp, MD, Karim N. Jamal, MD, Dennis M. Marcus, MD, Dante Pieramici, MD, Aamir A. Aziz, BS, Kiran C. Patki, MD, William Z. Bridges, Jr., MD, Samuel B. Barone, MD
Publikováno v:
Ophthalmology Science, Vol 2, Iss 2, Pp 100154- (2022)
Purpose: To establish the safety, tolerability, pharmacokinetics, and pharmacodynamics of an intravitreal injection of recombinant human complement factor H (CFH), GEM103, in individuals with genetically defined age-related macular degeneration (AMD)
Externí odkaz:
https://doaj.org/article/007c8c367e964d47b7fc962c7e0acaa8
Autor:
Gillian Bubb, Bert Yao, Sandra Rojas-Caro, Mercè Pineda, Xiaoping Zhang, Maria L. Escolar, Amy Cinar, Yang Dai, Kiran C. Patki, Geoff J M Parker, Chester B. Whitley, Suresh Vijay
Publikováno v:
Molecular genetics and metabolism. 126(2)
Mucopolysaccharidosis IIIB is caused by a marked decrease in N-acetyl-α-d-glucosaminidase (NAGLU) enzyme activity, which leads to the accumulation of heparan sulfate in key organs, progressive brain atrophy, and neurocognitive decline. In this open-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::642b9af9407e89ac1fc58ae2dac3dd04
https://pubmed.ncbi.nlm.nih.gov/30635159
https://pubmed.ncbi.nlm.nih.gov/30635159
Novel NAGLU variants associated with MPS IIIB and in vitro analysis of residual enzymatic activities
Autor:
Nina K. Jain, Maria L. Escolar, Suresh Vijay, Chris Forbes, Rui-ru Ji, Andrew Hutchinson, Kiran C. Patki, Chester B. Whitley, Frits A. Wijburg, Roberto Giugliani, Gillian Bubb
Publikováno v:
Molecular Genetics and Metabolism. 120:S71
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea8cec67be2fd9315d9390d65abd41fb
https://doi.org/10.1016/j.ymgme.2016.11.167
https://doi.org/10.1016/j.ymgme.2016.11.167
Autor:
Geoff J M Parker, Anthony Rossomando, Kiran C. Patki, Anthony G. Quinn, Suresh Vijay, Sandra Rojas-Caro, Mark C. Leavitt, Victoria Riches, Caleb Roberts, Tracey Kemp
Publikováno v:
Molecular Genetics and Metabolism. 114:S121-S122
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::778126bdb2e6ad21671fdc99370bbb45
https://doi.org/10.1016/j.ymgme.2014.12.279
https://doi.org/10.1016/j.ymgme.2014.12.279
Autor:
Leah M. Hesse, Lisa L. von Moltke, Jerold S. Harmatz, David J. Greenblatt, Michael H. Court, Kiran C. Patki
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 308(3)
We studied age-related changes in enzyme kinetic parameters in human liver microsomes (HLMs) in vitro, using triazolam (TRZ), an index of CYP3A activity. HLMs were prepared from male livers from four age groups, n = 5 per group: A (14-20 years), B (2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb7e61d71f648757df2cb847b636a988
https://pubmed.ncbi.nlm.nih.gov/14634046
https://pubmed.ncbi.nlm.nih.gov/14634046
Publikováno v:
Clinical Pharmacology & Therapeutics. 75:P83
We evaluated the potential for inhibition of CYP3A4 and CYP3A5 using seven mechanism-based inhibitors: troleandomycin (TAO), erythromycin (ERY), 6′, 7′-dihydroxybergamottin (DHB), diltiazem (DIL), verapamil (VER), ethynyl estradiol (EE) and riton
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e34826c36dcab8ead707db845e51dec1
https://doi.org/10.1016/j.clpt.2003.11.316
https://doi.org/10.1016/j.clpt.2003.11.316
Publikováno v:
Clinical Pharmacology & Therapeutics. 73:P18-P18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8a94799397538330a1bba6505a7b2b3
https://doi.org/10.1016/s0009-9236(03)90420-6
https://doi.org/10.1016/s0009-9236(03)90420-6
Publikováno v:
Journal of Pharmacy & Pharmacology; Aug2004, Vol. 56 Issue 8, p963-966, 4p